We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Verona Pharma Plc | LSE:VRP | London | Ordinary Share | GB00BYW2KH80 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 55.00 | 45.00 | 65.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMVRP LONDON, Sept. 01, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, is pleased to announce the appointment of Stifel Nicolaus Europe Limited as its Nominated Adviser and Sole Broker with immediate effect. About Verona Pharma plc Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. Verona Pharma's product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF), and potentially asthma. For further information, please contact: Verona Pharma plc Tel: +44 (0)20 3283 4200 Jan-Anders Karlsson, Chief Executive Officer info@veronapharma.com Stifel Nicolaus Europe Limited (Nominated Adviser Tel: +44 (0)20 7710 7600 and UK Broker) Stewart Wallace / Jonathan Senior / Ben Maddison SNELVeronaPharma@stifel.com ICR, Inc. (US Media and Investor Enquiries) Darcie Robinson Tel: +1 203 682 8379 Darcie.Robinson@icrinc.com Stephanie Carrington Tel: +1 646 277 1282 Stephanie.Carrington@icrinc .com FTI Consulting (UK Media and Investor Enquiries) Tel: +44 (0)20 3727 1000 Simon Conway / Stephanie Cuthbert / veronapharma@fticonsulting. Natalie Garland-Collins com This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Verona Pharma plc via Globenewswire http://www.veronapharma.com/
(END) Dow Jones Newswires
September 01, 2017 02:00 ET (06:00 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year Verona Pharma Chart |
1 Month Verona Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions